Poland – Medicinal products for the blood and blood-forming organs – HUMANIZOWANE PRZECIWCIAŁO monoklonalne będące inhibitorem szlaku krzepnięcia zależnego od czynnika tkankowego - koncizumab wraz z sukcesywnymi dostawami do ośrodków leczenia hemofilii i pokrewnych skaz krwotocznych oraz domów pacjentów (za które uznaje się miejsce zamieszkania lub pobytu stałego pacjenta); znak postępowania: ZZP.ZP.411.160.2026

The subject of the order covers the supply to Direct Recipients (Hemophilia Treatment Centers and Related Bleeding Disorders) of a humanized monoclonal antibody that is an inhibitor of the tissue factor-dependent coagulation pathway - concizumab, along with administration kits - hereinafter referred to as the "medicinal product", for the purpose of securing the treatment of patients with inhibitor-complicated hemophilia B, within the framework of the implementation of the health policy program of the minister responsible for health entitled "National Program for the Treatment of Patients with Hemophilia and Related Bleeding Disorders for the years 2024-2028", hereinafter referred to as the "MZ program", as well as the supply of administration kits, organisation of deliveries to patients' homes, which are considered to be the place of residence or permanent stay of the patient, for the indicated number of patients indicated by the National Blood Centre (hereinafter NCK), collection and disposal of single-use equipment and medical waste, ensuring strict records of the delivered medicinal product with control of drug use through the implementation of an electronic diary, development and preparation of informational materials on the safe use of medicinal products for all patients and training of all patients in the safe use of the medicinal product no later than the day of the first delivery and delivery of containers for medical waste for all patients, meeting the requirements in the scope of applicable regulations, on the principles specified in the SWZ.